Ari Joseph Rosenberg MD

Oncology•Chicago, IL

Head & Neck Cancer

Assistant Professor of Medicine

Join to View Full Profile

5841 S. MARYLANDM/C 2115Chicago, IL 60637
Phone+1 773-702-6149
Fax+1 773-702-3163

Summary

I am Assistant Professor of Medicine at the University of Chicago. My academic interest is in developing novel therapeutic strategies for patients with head and neck cancer. As a clinical investigator, I develop and conduct clinical trials for patients with head and neck cancer. My particular focus is incorporating novel therapeutics and immunotherapeutic strategies for the treatment of head and neck cancer, as well as developing strategies to reduce treatment-related toxicity.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2013 - 2016
Tel Aviv University SacklerClass of 2013, MD
University of Illinois at Urbana-ChampaignBS, Chemistry, Music, Cum Laude, 2004 - 2008

Certifications & Licensure

IL State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy Start of enrollment: 2019 Jan 16
RECRUITING
PHASE1
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer Start of enrollment: 2020 Oct 01
Completed
Phase 1
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer Start of enrollment: 2022 Oct 17
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer Start of enrollment: 2023 Mar 07
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers Start of enrollment: 2024 Jul 17
RECRUITING
PHASE1, PHASE2
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 2023 Mar 01
Withdrawn
Phase 1
Roles: Contact
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.
Dinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, Raghda Abu Shareb, Manu Prasad
Neoplasia. 2025-05-01
1 citations
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Hanna M Hieromnimon, Anna Trzcinska, Frank T Wen, Frederick M Howard, James M Dolezal
Oral Oncology. 2025-04-01
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized C...
Ari J Rosenberg, Aditya Juloori, Michael J Jelinek, Nishant Agrawal, John F Cursio
JAMA Oncology. 2025-03-06

Press Mentions

Immunotherapy with Chemotherapy Effective for HPV-Negative Head and Neck CancerMarch 12th, 2025
Chemo-Immunotherapy Approach Shows Potential Benefit in Patients with Advanced HPV-Negative Head and Neck CancerMarch 6th, 2025
Chemo-Immunotherapy Exhibits Promising Efficacy in Advanced HPV-Negative Head and Neck Cancer PatientsMarch 6th, 2025
Join now to see all

Professional Memberships